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ABSTRACT  
Objective: The purpose of this study is to investigate and compare the 
Gingival Index and the Plaque Index in a population treated with 2 probiotic 
food supplies (Reuterin Os® and Carioblis®) for two months. 
Material and Methods: The sample was composed of 92 patients suffering 
from gingivitis, divided into 4 groups: the first received only causal 
treatment (group A – control group), the second and the third (group B and 
C – test group) took respectively 1 and 2 tablet of probiotic food supplement 
Ruterin Os® every day for 60 days, the fourth (group D– test group) took 1 
tablet of probiotic food supplement Carioblis® every day for 60 days. 
The patients were visited every 14 days. Statistical analysis was performed 
to compare the control group to test groups after 2 months and to compare 
each index from the beginning to the end of treatment. 
Result: The study showed that the use of the probiotics RuterinOs® or 
Carioblis® in combination with causal treatment in patients with gingivitis 
led to a statistically significant improvement in plaque indices (PI) and 
gingival inflammation indices (GI) compared to the control group subjected 
only to causal treatment. The analysis of the data also highlighted a better 
result for patients who took 1 tablet of RuterinOs® every day for 2 months. 
Conclusion: The Authors can deduce that the somministration of one daily 
tablet of ReuterinOs® can bring benefits to oral health.  
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I. INTRODUCTION 
Gingivitis and periodontitis are historically considered to 
be among the most important global oral health disorders and 
their distribution and severity can vary in different parts of 
the world, from country to country or from region to region. 
Being able to maintain good oral health thus avoiding that a 
situation of gingivitis degenerates into periodontitis means 
preventing or postponing some chronic diseases [1]. 
Gingivitis is defined as an inflammatory condition 
affecting the soft tissues surrounding the tooth. It is a direct 
immune response, in reaction to the microbic plaque present 
on the dental surface which causes inflammation of the 
epithelial and connective tissue. It is a reversible condition 
without consequences if good home oral hygiene and 
adequate professional oral hygiene are performed [2]-[8]. 
When the oral biofilm, the main etiological factor of 
gingivitis, reaches maturity, is established a relationship 
between the host and the microbic species. The inflammatory 
by-products, together with the bacterial plaque, endotoxins 
and metabolic products begin the process of periodontal 
destruction [9]. 
The causal treatment proposed for periodontal diseases 
involves mechanical-instrumental treatment associated with 
the use of chemical-pharmacological aids and the patient's 
education and motivation for correct daily home oral hygiene; 
although this treatment method is commonly accepted and 
used, research and progress in the medical-scientific field 
have made possible to use additional methods or therapeutic 
strategies, including probiotics to inhibit the development of 
oral biofilm and reduce the cascade of harmful immune and 
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There are currently eight known classes of probiotics: 
seven from bacteria and one from yeasts. The most common 
probiotics belong to the generic strains of Lactobacillus and 
Bifidobacterium [1]. 
Probiotics can have a medical role as a microbial 
preparation and a functional role through nutrition. They are 
therefore provided in four different basic ways: 
• as a culture concentrated inside drinks or food; 
• in prebiotic fibers; 
• in a milk-based food (eg dairy products); 
• as cellular concentrates packaged in dietary supplements. 
Within the "macro-set" of antibiotics there is a subset of 
bacteriocins. The latter act selectively against specific 
bacterial strains or species and appear capable of eliminating 
or interfering with the growth of other bacteria genetically 
"close" to the inhibiting bacterium. Furthermore, unlike 
viruses, are considered safe by the Food and Drug 
Administration for administration in humans and have 
therefore gained popularity in research in the field of 
probiotics [14]-[16]. 
From the side effects point of view, inhibition between 
species, obtained through bacterial interference mediated by 
natural antibiotics such as bacteriocins, is preferable to the 
use of synthetic antibiotic agents, natural antibiotics cause a 
minor collateral reduction of non-pathogenic bacteria 
because the antimicrobial spectrum acts on bacteria in the 
immediate vicinity; for this reason, bacteriocin-producing 
bacteria are considered a sensible approach to pathogen 
control [14]. 
The action of probiotics in the oral cavity could be similar 
to that which occurs at the intestinal level. In fact, probiotics, 
in order to carry out their action, must be able to: 
- withstand oral conditions, 
- resist environmental defense mechanisms, 
- adhere to the saliva-coated surface, 
- colonize the mouth, 
- proliferate to inhibit oral pathogens [9-17]. 
The strategy action of probiotics is therefore based on the 
modifications of the potential pathogenic bacteria present in 
the biofilm, interfering with the growth and development of 
periodontal pathogens, replacing pathogenic microorganisms 
with beneficial bacteria, and preventing colonization by 
periodontal pathogens [18].  
Probiotics are thought to work through a number of 
different mechanisms including: 
• competition with potential pathogens for nutrients or for 
sites of adhesion with enterocytes, 
• degradation of toxins, 
• chemical inhibition of pathogenic bacteria: 
➢ lowering the pH, 
➢ producing inhibiting compounds, 
➢ reducing the availability of surfaces for colonization 
by other bacteria. 
• stimulation of the non-specific immune response and 
modulation of the cellular and humoral immune response 
through the production of immunoglobulins (IgG), defensins 
and cytokines and the decrease of metalloproteinases (MMP) 
[1], [19]-[22]. 
 
II. MATERIAL AND METHODS 
The purpose of this retrospective study was to investigate 
and compare the effects of probiotics contained in the 
commercial products ReuterinOs® (Nóos S.r.l., Roma, Italy) 
and Carioblis® (Omeopiacenza S.r.l, Piacenza, Italy) 
administered to patients with gingivitis after causal treatment 
and evaluate the trend in two months of the plaque and 
bleeding indexes, comparing the data to a control group. 
For this study 77 subjects with diagnosis of gingivitis, 
performed by evaluating the presence of a Plaque Index (PI, 
Löe and Silness, 1964)> 1.1 were recruited at the Sant'Andrea 
Hospital (Odontostomatologic Clinic – University of Eastern 
Piedmont) in Vercelli from january 2017 to january 2018. 
The selected patients had to fall within the following 
inclusion and exclusion criteria: 
Inclusion criteria: 
• be aged between 18 and 80; 
• be affected by gingivitis with indexes of gingival 
inflammation (PI, Löe and Silness, 1963) GI> 1.1 (moderate 
gingivitis) affecting permanent dental elements; 
• having expressed consent to the use of personal and 
health data when accessing the hospital. 
• presence in the mouth of the following teeth: 1.6-2.6-3.6-
4.6-1.1-2.1-3.1-4.1 (not implants) 
• no more than 4 teeth missing. 
General exclusion criteria: 
• Juvenile spongiotic gingivitis 
• Allergic and / or lactose intolerant patients; 
• patients with systemic conditions and / or conditions that 
could interfere with the results of the study, for example 
immunological disorders, pregnancy, ongoing drug therapy 
that could influence the signs of gingivitis, diabetes, 
cardiovascular disease, smokers (> 20 die cigarettes), use of 
oral antiseptics and mouthwashes, taking various antibiotics 
or probiotics in the 3 months prior to the study. 
Specific exclusion criteria for dental elements: 
• patients with evidence of neglect or lack of interest in 
the care of their oral hygiene, identifiable with PI index> 1.9 
(insufficient plaque control), or horizontal mobility of III 
degree and / or vertical mobility, 
• dental migration, 
• dental crowding, 
• ongoing orthodontic treatment, 
• incorrectly devitalized or necrotic elements, 
• elements with over-contour restorations (restorations 
and prosthetic crowns), 
• elements in primary or secondary occlusal trauma. 
During the first session, Plaque Index (Löe and Silness, 
1964) and Gingival Index (GI) (Löe and Silness, 1963) were 
measured on the mesial, distal, lingual / palatal and vestibular 
surfaces of the teeth: 1.6-2.6-3.6-4.6-1.1-2.1-3.1-4.1 (first 
molars and upper and lower central incisors on the right and 
left). 
After the acquisition of consent to treatment and after 
causal treatment (scaling and root planning), the patient 
deemed suitable was assigned a randomized protocol: group 
A (control group) or group B, C, or D (test groups) and a 
second, a third, a quarter and a fifth appointment was set at 
the clinic, each 14 days, for the assessment of the health status 
of the gingival tissues (T0, T1, T2, T3, T4). Each time the PI 
and GI indices were detected on the same dental elements: 
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mesial, distal, lingual / palatal, and vestibular surfaces of 1.6-
2.6-3.6-4.6-1.1-2.1-3.1-4.1 (first molars and upper and lower 
central incisors right and left). All data was collected 
anonymously. 
After carrying out the causal treatment, each patient 
included in the study was assigned a different protocol (21 for 
control group, 20 for test group B, 20 for test group C and 16 
for test group D): 
• Control group (A): after causal therapy, the patient 
cleaned the oral cavity daily after meals using a toothbrush 
and devices for oral interdental hygiene (at least twice a day 
morning and evening). Protocol A included periodic checks 
to evaluate the progression of gingivitis only after causal 
treatment. 
• Group B: after causal treatment, the patient cleaned the 
oral cavity daily after meals using a brush and interdental oral 
hygiene aids (at least twice a day morning and evening) and 
took one Reuterin Os® tablet for 60 days, dissolving it inside 
the oral cavity in the evening after home oral hygiene. After 
taking ReuterinOs®, the patient abstained from smoking, did 
not take food or drink and did not rinse. 
• Group C: the patient after causal therapy cleaned the oral 
cavity daily after meals using a brush and interdental oral 
hygiene aids (at least twice a day morning and evening) and 
took two ReuterinOs® tablets for 60 days, dissolving it inside 
the oral cavity in the evening after home oral hygiene. After 
taking ReuterinOs®, the patient abstained from smoking, did 
not take food or drink and did not rinse. 
• Group D: after causal therapy, the patient cleaned the 
oral cavity daily after meals using a brush and interdental oral 
hygiene aids (at least twice a day morning and evening) and 
took 1 tablet of Carioblis®. After taking Carioblis®, the 
patient abstained from smoking, did not take food or drink 
and did not perform other rinses. 
Participants were prescribed quantities of Reuterin Os® or 
Carioblis® probiotic food supply equal to use for 60 days. 
Reuterin OS® tablets is a food supplement containing the 
patented association of two strains of lactic ferments: 
lactobacillus reuteri DSM 17938 and lactobacillus reuteri 
ATCC PTA 5289. It is useful for making an additional 
portion of lactobacilli to the diet, containing sucralose which 
contributes to the maintenance of the tooth mineralization. It 
is recommended to take 2 tablets a day to be dissolved slowly 
in the mouth, preferably between meals, as stated by the 
producer. Carioblis® is a food supplement based on a special 
probiotic strain, streptococcus salivarius BLIS™ M18, 
useful to prevent the cariogenic processes and the periodontal 
disorders sustained above all by streptococcus mutans. The 
probiotic is capable of producing four salivaricins (A, M, 9 
and MPS) which oppose the growth of streptococcus mutans 
and streptoccus sobrinus, the main defendants in the 
cariogenic processes, and of other bacterial species involved 
in oral dysbiosis. It also releases dextrinase, an enzyme that 
reduces plaque formation, and urease, which counteracts the 
acidity of the oral cavity. It is recommended to be taken in the 
evening, before going to bed (1 tablet per day). 
The gingival measurements were performed using a 
PCPNC and / or Williams type millimeter probe. 
 
A. Statistical Analysis 
The data obtained were subjected to statistical analysis 
using Social Science Statistic software 
(www.socscistatistics.com). 
The periodontal PI and gingival indexes GI were analyzed 
at T4 by comparing the control group to groups B, C, and D. 
Furthermore, the averages of PI and GI at T4 with respect to 
T0 were compared within each group by means of t Student 
(Table I and II). 
The normal distribution of GI and PI values for each 
patient was analyzed using the Kolmogorov-Smirnov test. At 
T0 the values are normally distributed for both indices. 
 
III. RESULTS 
The final sample was made up of 77 patients, 21 for the 
control group, 20 for group B, 20 for group C and 16 for 
group D. 
The means were compared through the Student t test 
between PI at T0 and T4 per group of teeth (1.6-2.6-3.6-4.6-
1.1-2.1-3.1-4.1) and between the GI at TO and T4 per group 
of teeth with Student t test for paired data (graph 1; graph 2). 
A. Plaque Index Analysis (PI) 
As regards the PI of group B, the difference between T0 
and T4 is statistically significant for p <0.05, with t = -33.16. 
For the PI of group C, the difference between T0 and T4 is 
statistically significant for p <0.05, with t = -21.31. 
For the PI of group D the difference between T0 and T4 is 
statistically significant for p <0.05, with t = -26.94. 
For the PI of the control group the difference between T0 
and T4 is statistically significant for p <0.05, with t = -16.06, 
demonstrating that even periodontal treatment without 
subministration of any probiotic is effective in leading to a 
reduction in the plaque index. 
Therefore, the Authors analyzed in detail which treatment 
was significantly more effective than the others. With Mann 
- Whitney test for unpaired data without normal distribution, 
which was not found for PI values for all groups in T4, PI 
values were compared in T4 in the following pairs: 
Control group – group B; 
Control group – group C; 
Control group – group D; 
Group B – group C; 
Group B – group D; 
Group C – group D. 
The difference was statistically significant for all test 
groups (B, C, D) compared to the control group (A), while the 
difference within the same test groups was not statistically 
significant. 
B. Gingival Index Analysis (GI) 
As regards the GI of group B, the difference between T0 
and T4 is statistically significant for p <0.05, with t = -35.79. 
For the GI of group C the difference between T0 and T4 is 
statistically significant for p <0.05, with t = -29.40. 
For the GI of group D the difference between T0 and T4 is 
statistically significant for p <0.05, with t = -26.85. 
For the GI of the control group, the difference between T0 
and T4 is statistically significant for p <0.05, with t = -15.84, 
demonstrating that periodontal treatment without 
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administration of any probiotic is also effective in leading to 
a reduction in the index of gingival inflammation. 
The Authors then analyzed in detail which treatment was 
significantly more effective than the others. With the Mann - 
Whitney test for unpaired data without normal distribution, 
which was not found for the GI values for all groups in T4, 
the GI values were compared to T4 in the following pairs: 
Control group – group B; 
Control group – group C; 
Control group – group D; 
Group B – group C; 
Group B – group D; 
Group C – group D. 
The difference was statistically significant for all test 
groups (B, C, D) compared to the control group (A), and for 
group B compared to groups C and D. The difference between 
group C and group D was not statistically significant. 
 












Control group 1.35 0.36 0.31 0.34 0.49 
Test group B 1.34 0.10 0.03 0.01 0.01 
Test group C 1.30 0.16 0.11 0.07 0.07 
Test group D 1.38 0.42 0.21 0.12 0.10 
 












Control group 1.22 0.41 0.34 0.32 0.45 
Test group B 1.23 0.34 0.23 0.15 0.11 
Test group C 1.26 0.31 0.24 0.20 0.17 
Test group D 1.34 0.56 0.34 0.19 0.14 
 
 
Fig. 1. Gingival index from T0 to T4 for control and test groups. 
 
IV. DISCUSSION 
Taking preventive measures against periodontal diseases 
as well as their treatment is an additional component to the 
practice of dental hygiene. The prevalence of periodontal 
disease is difficult to be accurately defined, but the most 
recent estimates made by the Center for Disease Control and 
Prevention (CDC) indicate that 8.51% of American adults 
between 20 and 64 years old have periodontal disease. 
Subsequent studies have determined that more than half of 
Americans have gingivitis [23]-[26]. 
There is scientific evidence showing that adding antibiotics 
or chlorhexidine to periodontal therapy with scaling and root 
planning improves periodontal health. Despite this, the CDC 
has defined antibiotic resistance as a growing problem and a 
direct result of the widespread use of antibiotics, and 
prolonged use of chlorhexidine can lead to side-effects like 
loss of taste, taste perturbation and numb feeling of the mouth 
[25]. In this regard, the role of the dental hygienist comes into 
play in knowing how to recommend antibiotic therapy only 
at the right time and in knowing how to consider any other 
possible strategies such as the administration of probiotics 
[26], [27]. 
The data obtained from the observational survey through 
the data collection of the PI plaque index and GI gingival 
inflammation in five times T0, T1, T2, T3 and T4 according 
to protocols A, B, C and D allowed to define whether the use 
of Reuterin Os® and Carioblis® probiotics, associated with 
causal therapy, they will or may not benefit the patient's oral 
health. 
Therefore, it was shown that all the test groups (B, C, D) 
compared to the control group developed a statistically 
significant improvement in plaque indices (PI) at T4 without 
significant differences between them. As regards the gingival 
indexes (GI), however, the test groups show significant 
improvements compared to the control group but also to each 
other: group B in fact shows better results than groups C and 
D, which instead show no significant differences between 
them. 
As regards the PI values one month after the start of 
treatment (T2), the PI of the 2 test groups that took 
ReuterinOs® is lower than the group that took Carioblis® 
(test group D) and then the control group, which instead are 
similar to each other. Seemingly, 4 weeks are not a sufficient 
period of time to notice the differences with the use of 
Carioblis®; another interpretation may be the highest starting 
PI of the test group D. As stated before, in T4 the test groups 
(B, C and D) all have significantly lower average values of PI 
(p<0,05) than the control group (group A). 
 
 
Fig. 2. Plaque index from T0 to T4 for control and test groups. 
 
As regards the GI, after 2 weeks from the start of the 
treatment (T1) the average values of the control group and of 
the D test group are similar between each other and higher 
than the test groups that took ReuterinOs®, testifying a 
possible slower effect of the probiotic Carioblis® compared 
to the probiotic ReuterinOs®. In T4 the test groups (B, C and 










Mean GI T0 Mean GI T1 Mean GI T2 Mean GI T3 Mean GI T4
Control group Test group B
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than the control group (group A). 
It can also be noted that at T4 both GI and PI increase for 
the control group from T3. It should draw attention to the 
constant need for oral hygiene and the recurrence of plaque if 
no other intervention is done. This is not noted in the 3 test 
groups. 
Researches conducted on the administration of probiotics 
show that they cannot cause harmful effects on patients who 
have an adequate immune system. There are currently eight 
probiotics considered safe: 
1. Lactobacillus reuteri,  
2. Lactobacillus casei,  
3. Lactobacillus acidophilus,  
4. Bifidobacterium lactis, 
5.  Bifidobacterium longum,  
6. Saccharomyces cerevisiae,  
7. Saccharomyces cerevisiae, 
8. Carnobacterium maltaromaticum. 
Any microorganism is capable of causing bacteremia, 
especially in patients with serious underlying diseases or 
immunocompromised patients. However, the present 
literature supports the conclusion that the incidence of 
Lactobacillus bacteraemia is inconsistent and that all cases 
where individuals were recorded had other systemic diseases 
such as diabetes, cardiovascular disease, gastrointestinal 
disease, malignant tumors, or transplanted organs [19]-[28]. 
Probiotics therefore represent a new area of research for 
oral health care. Examination of the close relationship 
between diet and oral health can potentially be regulated with 
a variety of different products, such as conventional foods 
(for the consumption of general populations), dietary 
supplements (intended not as meals but as oral dietary 
supplements), medical foods (foods used under medical 
supervision for patients who need a particular diet in support 
of a medical condition), medications (to treat, treat, relieve, 
diagnose diseases) and additives. Recent engineering studies 
on metabolic expression and protein expression have 
highlighted the enzymatic and immunomodulatory effect of 
probiotics: this could allow their use in a greater number of 
healthy patients and individuals. Furthermore, the 
implantation and persistence of probiotics are an important 
requirement for their activity and will have to rely on the 
synchronized supply of growth factors of the probiotic itself 
[1], [29]-[31].  
 
V. CONCLUSIONS 
This research showed that the use of the ReuterinOs® or 
Carioblis® food supplement probiotic in combination with 
causal therapy, in patients with gingivitis, led to a statistically 
significant improvement in plaque indices (PI) and gingival 
inflammation indices (GI) compared to the control group 
subjected only to causal therapy.  
The analysis of the data also highlighted a better result for 
patients assigned to group B than for patients assigned to 
group C or D as regards the index of gingival inflammation 
GI. We can therefore deduce that the administration of only 
one daily tablet of ReuterinOs® Probiotic is sufficient to feed 
a recolonization of the oral microflora and to bring benefits 
to oral health compared to the administration of 1 tablet of 
Carioblis® or two tablets of ReuterinOs® probiotic food 
supply, as in the latter case 2 tablets a day could 
exaggeratedly alter the microflora. Thanks to the evidence 
demonstrated by the clinical data just illustrated, for daily 
clinical practice for both dental hygienist and dentist it is 
recommended to consider a possible coadjutant for 
periodontal treatment the prescription of 1 tablet per day for 
60 days of lactobacillus reuteri DSM 17938 and lactobacillus 
reuteri ATCC PTA 5289, thus considering probiotics as 
important support to causal therapy for the maintenance of 
correct oral hygiene. 
Microbiological and medical research in probiotic food 
supplies is still in their origin and numerous key points need 
clarification, so further studies are needed. 
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